milrinone has been researched along with furosemide in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Riley, CM | 1 |
| Alexander, KS; Fink, JM; Honisko, ME; Mauro, VF; Militello, MA | 1 |
| Abdul-Khaliq, H; Ewert, P; Lange, PE; Nagdyman, N; Peters, B; Schubert, S | 1 |
| Beierwaltes, WH | 1 |
| Kurien, S; Miller, WL; Warfield, KT; Wood, CM | 1 |
| Ahmad, T; Milano, CA; Patel, CB; Rogers, JG | 1 |
| Donnell, SA; Steele, RW; Young, TW | 1 |
| Charbonneau, É; Cinq Mars, A; Dubois, M; Sénéchal, M; Soucy-Giguere, MC | 1 |
1 review(s) available for milrinone and furosemide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
13 other study(ies) available for milrinone and furosemide
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Stability of milrinone and digoxin, furosemide, procainamide hydrochloride, propranolol hydrochloride, quinidine gluconate, or verapamil hydrochloride in 5% dextrose injection.
Topics: Digoxin; Drug Combinations; Drug Stability; Drug Storage; Furosemide; Glucose; Indicators and Reagents; Milrinone; Procainamide; Propranolol; Pyridones; Quinidine; Solutions; Temperature; Verapamil | 1988 |
Compatibility of argatroban with selected cardiovascular agents.
Topics: Amiodarone; Anticoagulants; Arginine; Cardiovascular Agents; Drug Interactions; Drug Therapy, Combination; Fenoldopam; Furosemide; Humans; Infusions, Parenteral; Lidocaine; Milrinone; Natriuretic Peptide, Brain; Nitroglycerin; Nitroprusside; Pipecolic Acids; Sulfonamides; Vasopressins | 2004 |
Left ventricular conditioning in the elderly patient to prevent congestive heart failure after transcatheter closure of atrial septal defect.
Topics: Aged; Aged, 80 and over; Cardiac Catheterization; Cardiotonic Agents; Catheterization; Diuretics; Dopamine; Drug Therapy, Combination; Furosemide; Heart Failure; Heart Septal Defects, Atrial; Heart Ventricles; Humans; Injections, Intravenous; Middle Aged; Milrinone; Retrospective Studies; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2005 |
cGMP stimulates renin secretion in vivo by inhibiting phosphodiesterase-3.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 5; Furosemide; Kinetics; Male; Milrinone; Nitric Oxide; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Purinones; Rats; Rats, Sprague-Dawley; Renin; Second Messenger Systems | 2006 |
Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide.
Topics: Aged; Cardiotonic Agents; Creatinine; Diuretics; Dobutamine; Dopamine; Drug Therapy, Combination; Female; Furosemide; Glomerular Filtration Rate; Heart Failure; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Kidney; Male; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Survival Rate; Urine | 2006 |
When the heart runs out of heartbeats: treatment options for refractory end-stage heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiotonic Agents; Carvedilol; Diuretics; Drug Therapy, Combination; Evidence-Based Medicine; Furosemide; Heart Failure; Heart Transplantation; Heart-Assist Devices; Humans; Lisinopril; Male; Middle Aged; Milrinone; Propanolamines; Severity of Illness Index; Spironolactone | 2012 |
A toddler in distress.
Topics: Abdominal Pain; Cardiomyopathy, Dilated; Cardiotonic Agents; Child, Preschool; Diagnosis, Differential; Diuretics; Furosemide; Humans; Lethargy; Male; Milrinone; Myocarditis | 2015 |
Temporary left ventricular assist device for complete recovery from reversible acute heart failure due to tumor necrosis factor-α inhibitor.
Topics: Adult; Arthritis; Cardiomyopathy, Dilated; Cardiotonic Agents; Crohn Disease; Etanercept; Female; Furosemide; Heart Failure; Heart-Assist Devices; Humans; Infliximab; Milrinone; Tumor Necrosis Factor-alpha | 2019 |